Urovant Sciences (UROV) Misses Q3 EPS by 10c

Urovant Sciences (NASDAQ: UROV) reported Q3 EPS of ($0.87), $0.10 worse than the analyst estimate of ($0.77).

“Urovant Sciences continued to make progress on several clinical programs for vibegron, an investigational beta-3 adrenergic agonist, demonstrating our commitment to urology,” said Keith A. Katkin, chief executive officer of Urovant. “We remain on schedule to report topline data from EMPOWUR, our robust international Phase 3 trial evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of overactive bladder by the end of March 2019.”

Mr. Katkin continued, “Furthermore, we initiated a Phase 2a study of vibegron in women with IBS-associated abdominal pain in December 2018. And we recently received a response from the FDA to our proposed protocol for our pivotal Phase 3 study of vibegron in men with overactive bladder and benign prostatic hyperplasia. This is an important supplemental program for vibegron as there is currently no treatment for men with concomitant OAB and BPH.”

For earnings history and earnings-related data on Urovant Sciences (UROV) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Z Squared outlines AI power strategy and Paradox Data acquisition